Cite this DOI

Longman Publishers (2020). Aptamer: A New Class of Oligonucleotide for Therapeutic and Diagnostic Use - Review. *Journal of Science & Technology*, *5*(3), 19–24. https://doi.org/10.46243/jst.2020.v5.i3.pp19-24

@article{anon2020aptamer,
  title     = {{Aptamer: A New Class of Oligonucleotide for Therapeutic and Diagnostic Use - Review}},
  journal   = {Journal of Science \& Technology},
  year      = {2020},
  month     = {apr},
  volume    = {5},
  number    = {3},
  pages     = {19--24},
  publisher = {Longman Publishers},
  issn      = {2456-5660},
  doi       = {10.46243/jst.2020.v5.i3.pp19-24},
  url       = {https://doi.org/10.46243/jst.2020.v5.i3.pp19-24},
  language  = {en},
  abstract  = {Recently, aptamers get the attention of many scientist, because they have all advantages of antibodies which found in human body. They also have unique merits like thermal stability, low cost, and many more. Aptamers are the short sequence nucleic acid with a high affinity and specificity. It is globally adopted as a one of the advance and promising drug delivery technique. These aptamers are produced by in vitro selection method using SELEX technique. This review contains the discussion on the aspect of design, unique properties, applications of aptamers to aid in cancer diagnosis, prevention and treatment under fine condition. Finally, several medical and analytical applications are presented.}
}

TY  - JOUR
TI  - Aptamer: A New Class of Oligonucleotide for Therapeutic and Diagnostic Use - Review
JO  - Journal of Science & Technology
PY  - 2020
DA  - 2020/04/29/
VL  - 5
IS  - 3
SP  - 19
EP  - 24
PB  - Longman Publishers
SN  - 2456-5660
LA  - en
AB  - Recently, aptamers get the attention of many scientist, because they have all advantages of antibodies which found in human body. They also have unique merits like thermal stability, low cost, and many more. Aptamers are the short sequence nucleic acid with a high affinity and specificity. It is globally adopted as a one of the advance and promising drug delivery technique. These aptamers are produced by in vitro selection method using SELEX technique. This review contains the discussion on the aspect of design, unique properties, applications of aptamers to aid in cancer diagnosis, prevention and treatment under fine condition. Finally, several medical and analytical applications are presented.
DO  - 10.46243/jst.2020.v5.i3.pp19-24
UR  - https://doi.org/10.46243/jst.2020.v5.i3.pp19-24
ER  -

{
    "type": "article-journal",
    "id": "10.46243/jst.2020.v5.i3.pp19-24",
    "DOI": "10.46243/jst.2020.v5.i3.pp19-24",
    "URL": "https://doi.org/10.46243/jst.2020.v5.i3.pp19-24",
    "title": "Aptamer: A New Class of Oligonucleotide for Therapeutic and Diagnostic Use - Review",
    "source": "Smart Scholars DOI Registry",
    "container-title": "Journal of Science & Technology",
    "issued": {
        "date-parts": [
            [
                2020,
                4,
                29
            ]
        ]
    },
    "volume": "5",
    "issue": "3",
    "page": "19-24",
    "publisher": "Longman Publishers",
    "language": "en",
    "abstract": "Recently, aptamers get the attention of many scientist, because they have all advantages of antibodies which found in human body. They also have unique merits like thermal stability, low cost, and many more. Aptamers are the short sequence nucleic acid with a high affinity and specificity. It is globally adopted as a one of the advance and promising drug delivery technique. These aptamers are produced by in vitro selection method using SELEX technique. This review contains the discussion on the aspect of design, unique properties, applications of aptamers to aid in cancer diagnosis, prevention and treatment under fine condition. Finally, several medical and analytical applications are presented.",
    "ISSN": "2456-5660"
}

From the record as registered (version 2) — the record and its history. Programs: https://registry.smartscholars.in/api.php?action=cite&doi=10.46243%2Fjst.2020.v5.i3.pp19-24 gives all four in one JSON answer.